Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Instagram Outage Disrupts Thousands of U.S. Users 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
BOULDER, Colo., Nov. 02, 2016 -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today announced that Chief Executive Officer, Jon Congleton will present a corporate overview at the 25th Annual Credit Suisse Healthcare Conference and the Stifel 2016 Healthcare Conference.
Details of the two presentations are as follows:
25th Annual Credit Suisse Healthcare Conference
Date: Tuesday, November 8th
Location: The Phoenician, Arizona
Presentation Time: 4:00 PM MST
Stifel 2016 Healthcare Conference
Date: Tuesday, November 15th
Location: The Lotte New York Palace Hotel, New York
Presentation Time: 10:15 AM EST
Individuals may access a live webcast of the conference presentations on the Nivalis website at www.nivalis.com under "IR Calendar" in the "News / Events" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Contacts: Investor Relations John Graziano 1-646-378-2942 [email protected] Media Relations Lindsay Rocco 1-862-596-1304 [email protected]
